Relyens
VC Fund
Lyon, France
Relyens is a global reference partner for healthcare providers and local authorities to manage the risks inherent in their operations
- Total investments:
- 16
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Relyens invests in
BiotechnologyHealth CareMedicalArtificial IntelligenceSoftware
Stages Relyens invests in
Series BSeries ASeedSeries CVenture - Series Unknown
Countries Relyens invests in
FranceIsraelSwitzerlandUnited States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dominique Godet
|
|||
Sandrine Pernette
|
|||
Investment Focus
Industry
- Biotechnology 6 (38%)
- Health Care 5 (31%)
- Medical 4 (25%)
- Artificial Intelligence 4 (25%)
- Software 3 (19%)
Stage
- Series B 7 (44%)
- Series A 3 (19%)
- Seed 2 (13%)
- Series C 1 (6%)
- Venture - Series Unknown 1 (6%)
Country
- France 10 (63%)
- Israel 1 (6%)
- Switzerland 1 (6%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dominique Godet
CEO
|
CEO | Total investments: 0 | Find email | |
|
Sandrine Pernette
Investment Director
|
Investment Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kimialys
|
Kimialys develops and sells proprietary and patented surface chemistry for biosensors, increasing their sensitivity and specificity to deliver reliable, rapid, and cost-effective diagnostic tests. It was founded in 2020 by Cyril Gilbert and Claude Nogues in Paris, Ile-de-France, France. | $4.2M / Seed / Dec 05, 2025 | |
BrainEver
|
BrainEver’s innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including metabolism and epigeneticstability.BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS).Beside Engrailed 1 in Parkinson Disease and ALS, BrainEver is currently generating a pipeline of 4 drug candidates targeting other neurodegenerative disease like Huntington Disease and Optic Neuropathies. | $38.8M / Series B / Jul 03, 2025 | |
DeepLife
|
DeepLife uses deep learning on multi-omics data to model cells and efficiently engineer their behavior.DeepLife is a biotech company with a mission to build the next generation of system biology. The company works in a highly collaborative translational manner, to facilitate the transition of discoveries from the laboratory to patients. Thecompany operates through collaboration with academic groups in their respective areas of expertise. | $10M / Series A / Dec 11, 2024 | |
Caresyntax
|
Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $80M / Series C / Aug 15, 2024 | |
SamanTree Medical
|
SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room. | $14M / Series B / Jul 16, 2024 | |
Pixee Medical
|
Pixee Medical is a manufacturing company that produces computer-assisted surgery solutions using computer vision and AI technologies. | $15.1M / Series B / Feb 08, 2024 | |
CarThera
|
CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders since.The company’s proprietary device called SonoCloud® is an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB) and allows a significantly increased concentration of therapeutic molecules to reachthe brain. | $41.1M / Series B / Jun 27, 2023 | |
Citalid
|
Citalid Cybersecurity is a French company whose ambition is to place the analysis of cybermenaces at the heart of the strategic decisions of its customers. An effective cyber defense today can not be limited to technical expertise alone, but must be conceived transversely. Citalid provides its clients with an online platform for analysis anddecision support based on three complementary pillars: knowledge of attack procedures; the organization of a common cyber defense through a controlled sharing of information; the assessment and anticipation of computer threats. Citalid innovates by identifying contexts conducive to cyber attacks by cross-checking cyber, geopolitical, economic, social, and other information. Its clients benefit not only from a tailor-made and operational mapping of the threats likely to target them, but also from the associated preventive defense axes. --- Citalid Cybersecurity is a company focused on cyber threat intelligence at the heart of its customers' strategic decisions. An efficient cyberdefense can not be limited to technical expertise anymore, but must be designed in a transversal way. Citalid is helping its customers with an online analysis platform for supporting the decision-making process by: increasing the knowledge about the attackers; organizing joined cyberdefense via controlled information sharing; evaluating and anticipating the cyber risk. Citalid innovates by identifying contexts to cyberattacks through the crossing of heterogenous information sources: cyber, geopolitics, economics, social, etc. Thus, its customers may not be affected by a specific problem, but also by the appropriate preventive lines of defense. | $11.6M / Series A / Oct 12, 2022 | |
Therapixel
|
Therapixel develops and commercializes AI-based software for breast cancer detection and characterization | $15.6M / Series B / May 12, 2022 | |
Manty
|
Manty is a business intelligence platform for public administrations that provides a tool to analyze their data quickly and easily. It helps public bodies manage fuse and visualize data with ease to make better decisions. Based in Paris, the company was founded by Mathieu Nohet, Joseph-Marie Valleix, and Lucas Gaillard in 2017. | $3.3M / Series A / Mar 16, 2022 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Relyens invest in?
Relyens invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 16 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Relyens?
Public channels for Relyens include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Relyens?
The team at Relyens includes Dominique Godet (CEO) and Sandrine Pernette (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
